Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
The global Adalimumab (Humira) and Biosimilar market was valued at US$ 23070 million in 2022 and is projected to reach US$ 16210 million by 2029, at a CAGR of -4.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report aims to provide a comprehensive presentation of the global market for Adalimumab (Humira) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab (Humira) and Biosimilar. This report contains market size and forecasts of Adalimumab (Humira) and Biosimilar in global, including the following market information:
Global Adalimumab (Humira) and Biosimilar Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Adalimumab (Humira) and Biosimilar Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Adalimumab (Humira) and Biosimilar companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab (Humira) and Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab (Humira) and Biosimilar Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab (Humira) and Biosimilar Market Segment Percentages, by Type, 2022 (%)
Syringe
Pen
Global Adalimumab (Humira) and Biosimilar Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab (Humira) and Biosimilar Market Segment Percentages, by Application, 2022 (%)
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Global Adalimumab (Humira) and Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab (Humira) and Biosimilar Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adalimumab (Humira) and Biosimilar revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Adalimumab (Humira) and Biosimilar revenues share in global market, 2022 (%)
Key companies Adalimumab (Humira) and Biosimilar sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Adalimumab (Humira) and Biosimilar sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adalimumab (Humira) and Biosimilar, market overview.
Chapter 2: Global Adalimumab (Humira) and Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Adalimumab (Humira) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adalimumab (Humira) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adalimumab (Humira) and Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Adalimumab (Humira) and Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adalimumab (Humira) and Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adalimumab (Humira) and Biosimilar Overall Market Size
2.1 Global Adalimumab (Humira) and Biosimilar Market Size: 2022 VS 2029
2.2 Global Adalimumab (Humira) and Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Adalimumab (Humira) and Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Adalimumab (Humira) and Biosimilar Players in Global Market
3.2 Top Global Adalimumab (Humira) and Biosimilar Companies Ranked by Revenue
3.3 Global Adalimumab (Humira) and Biosimilar Revenue by Companies
3.4 Global Adalimumab (Humira) and Biosimilar Sales by Companies
3.5 Global Adalimumab (Humira) and Biosimilar Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Adalimumab (Humira) and Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Adalimumab (Humira) and Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adalimumab (Humira) and Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Adalimumab (Humira) and Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Adalimumab (Humira) and Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Adalimumab (Humira) and Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Syringe
4.1.3 Pen
4.2 By Type - Global Adalimumab (Humira) and Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Adalimumab (Humira) and Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Adalimumab (Humira) and Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Adalimumab (Humira) and Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Adalimumab (Humira) and Biosimilar Sales & Forecasts
4.3.1 By Type - Global Adalimumab (Humira) and Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Adalimumab (Humira) and Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Adalimumab (Humira) and Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Adalimumab (Humira) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adalimumab (Humira) and Biosimilar Market Size, 2022 & 2029
5.1.2 Ankylosing Spondylitis
5.1.3 Rheumatoid Arthritis
5.1.4 Crohn’s Disease
5.1.5 Other
5.2 By Application - Global Adalimumab (Humira) and Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Adalimumab (Humira) and Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Adalimumab (Humira) and Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Adalimumab (Humira) and Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Adalimumab (Humira) and Biosimilar Sales & Forecasts
5.3.1 By Application - Global Adalimumab (Humira) and Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Adalimumab (Humira) and Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Adalimumab (Humira) and Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Adalimumab (Humira) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Adalimumab (Humira) and Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Adalimumab (Humira) and Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Adalimumab (Humira) and Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Adalimumab (Humira) and Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Adalimumab (Humira) and Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Adalimumab (Humira) and Biosimilar Sales & Forecasts
6.3.1 By Region - Global Adalimumab (Humira) and Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Adalimumab (Humira) and Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Adalimumab (Humira) and Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Adalimumab (Humira) and Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Adalimumab (Humira) and Biosimilar Sales, 2018-2029
6.4.3 US Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.4.4 Canada Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.4.5 Mexico Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Adalimumab (Humira) and Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Adalimumab (Humira) and Biosimilar Sales, 2018-2029
6.5.3 Germany Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.4 France Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.5 U.K. Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.6 Italy Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.7 Russia Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.5.9 Benelux Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Adalimumab (Humira) and Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Adalimumab (Humira) and Biosimilar Sales, 2018-2029
6.6.3 China Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.6.4 Japan Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.6.5 South Korea Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.6.7 India Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Adalimumab (Humira) and Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Adalimumab (Humira) and Biosimilar Sales, 2018-2029
6.7.3 Brazil Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.7.4 Argentina Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Adalimumab (Humira) and Biosimilar Sales, 2018-2029
6.8.3 Turkey Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.8.4 Israel Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
6.8.6 UAE Adalimumab (Humira) and Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Adalimumab (Humira) and Biosimilar Major Product Offerings
7.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.1.5 AbbVie Key News & Latest Developments
7.2 Eisai
7.2.1 Eisai Company Summary
7.2.2 Eisai Business Overview
7.2.3 Eisai Adalimumab (Humira) and Biosimilar Major Product Offerings
7.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.2.5 Eisai Key News & Latest Developments
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Company Summary
7.3.2 Cadila Healthcare Business Overview
7.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Major Product Offerings
7.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.3.5 Cadila Healthcare Key News & Latest Developments
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Company Summary
7.4.2 Torrent Pharmaceuticals Business Overview
7.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Major Product Offerings
7.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.4.5 Torrent Pharmaceuticals Key News & Latest Developments
7.5 Amgen
7.5.1 Amgen Company Summary
7.5.2 Amgen Business Overview
7.5.3 Amgen Adalimumab (Humira) and Biosimilar Major Product Offerings
7.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.5.5 Amgen Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Major Product Offerings
7.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Adalimumab (Humira) and Biosimilar Major Product Offerings
7.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.7.5 Novartis Key News & Latest Developments
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Company Summary
7.8.2 Samsung Bioepis Business Overview
7.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Major Product Offerings
7.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.8.5 Samsung Bioepis Key News & Latest Developments
7.9 Viatris
7.9.1 Viatris Company Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Adalimumab (Humira) and Biosimilar Major Product Offerings
7.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.9.5 Viatris Key News & Latest Developments
7.10 Pfizer
7.10.1 Pfizer Company Summary
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Adalimumab (Humira) and Biosimilar Major Product Offerings
7.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.10.5 Pfizer Key News & Latest Developments
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Company Summary
7.11.2 Fresenius Kabi Adalimumab (Humira) and Biosimilar Business Overview
7.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Major Product Offerings
7.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.11.5 Fresenius Kabi Key News & Latest Developments
7.12 Coherus
7.12.1 Coherus Company Summary
7.12.2 Coherus Adalimumab (Humira) and Biosimilar Business Overview
7.12.3 Coherus Adalimumab (Humira) and Biosimilar Major Product Offerings
7.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales and Revenue in Global (2018-2023)
7.12.5 Coherus Key News & Latest Developments
8 Global Adalimumab (Humira) and Biosimilar Production Capacity, Analysis
8.1 Global Adalimumab (Humira) and Biosimilar Production Capacity, 2018-2029
8.2 Adalimumab (Humira) and Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Adalimumab (Humira) and Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Adalimumab (Humira) and Biosimilar Supply Chain Analysis
10.1 Adalimumab (Humira) and Biosimilar Industry Value Chain
10.2 Adalimumab (Humira) and Biosimilar Upstream Market
10.3 Adalimumab (Humira) and Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Adalimumab (Humira) and Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
